Announcement:

A recent study by a team at Unilever has demonstrated the predictive power of NAM approaches for the comprehensive safety assessment of compounds by combining in vitro models with advanced computational techniques. They used the aProximate™ proximal tubule cell model to assess potential nephrotoxicity and renal transport kinetics.

Find out more

Home › Resources › Videos and webinars › Harnessing Advanced In Vitro Lung Assays for Compound Screening

Harnessing Advanced In Vitro Lung Assays for Compound Screening

Dr Fiona Leslie delivers a talk via LinkedIn live on sensitivity and throughput in the context of obtaining human-relevant data.

During the talk Dr Leslie shares details on:

How to accurately measure the effect of compounds on cilia activity of primary human small airway epithelial cell (SAEC) model using Cilia Beat Frequency assays and softwares
How to measure fibrotic marker expression at high-throughput in primary human lung fibroblasts with an advanced Fibroblast-to-Myofibroblast Transition Assay

Date: Thursday 5th June 2025

Published

June 5, 2025

Share on social media:

Don't miss out on our latest innovations: follow us on Linkedin

View Today

Please enter the required details to view the webinar. You are not automatically signing up for receiving marketing emails.

Book a Call